BeOne Medicines, TEVIMBRA, ZIIHERA, tislelizumab, zanidatamab, HER2-positive gastroesophageal adenocarcinoma, HERIZON-GEA-01, Phase 3 clinical trial, oncology, immunotherapy

San Carlos, California, U.S., October 23, 2026 BeOne Medicines Ltd. reported updated long-term survival findings from the Phase 3...